Tag Archives: Merck KGaA

Merck KGaA Announces Restructuring

By Guest Blogger | Published: March 6, 2012

Merck KGaA announced measures intended to reduce costs and increase efficiency to ensure the long-term success of its business model. The measures are part of a comprehensive transformation program that will be implemented in two phases. In the first two years, Merck plans to implement a new leadership organization, implement efficiency measures, and develop a [...]

Merck KGaA MS Drug on the Fast Track

By George Koroneos | Published: July 28, 2010

Merck KGaA received word July 25 that its application for the multiple sclerosis treatment Cladribine had received priority review status by FDA, decreasing the evaluation period from 10 months to six months, and closing the gap between Merck and the competition. “This is a critical milestone on the path to potential approval for short-course therapy with [...]

Posted in Strategy | Also tagged Cladribine, EMD Serono, Fereydoun Firouz, Food and Drug Administration, Gilenia, Merck Serono, Multiple Sclerosis, Novartis | Leave a comment